...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: A couple Q2 events for Zenith

BDAZ - I think you will find that dosing of the first combination cohort did not start until mid January so with luck we will be late into the third cohort or just starting the fourth.

It would be nice to get some info from the company. We should be getting to the point of an investor  update conference call for Zenith.

tada

Share
New Message
Please login to post a reply